Prof Axel Hauschild speaks with ecancer at the EADO 2018 congress in Barcelona on whether it is possible to cure advanced metastatic melanoma patients.
Prof Hauschild explains that there is promising data for use of the PD-1 antibodies and also for the combination of ipilimumab and nivolumab.
He explains that for patients with a metastatic disease such as isolated systemic metastasis similar results or better can be achieved through surgery.
He believes that one of the remaining challenges is the development of a biomarker that is easier to use particularly on patients with a low tumour load.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.